Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip De Keyser

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Current Rheumatology Reviews|November 15, 2011
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection PerspectiveFilip De Keyser
Arthritis Research & Therapy|June 24, 2010
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritisIsabelle Delabaye, Filip De Keyser,
Current Molecular Medicine|March 12, 2004
The histopathology of spondyloarthropathyDominique Baeten, Filip De Keyser
Plos One|September 5, 2014
Assessment of activity limitations with the health assessment questionnaire predicts the need for support measures in patients with rheumatoid arthritis: a multicenter observational studyXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Clinical and Experimental Rheumatology|August 1, 2013
Construction and psychometric properties of the Belgian Rheumatoid Arthritis Disability Assessment (BRADA) questionnaire: a new tool for the evaluation of activity limitations in patients with rheumatoid arthritisXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Plos One|January 23, 2016
Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid ArthritisXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Cytokine|March 7, 2006
Anti-TNF-alpha therapy in ankylosing spondylitisFilip De Keyser, Filip Van den Bosch, Herman Mielants
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Ocular Immunology and Inflammation|July 30, 2015
Fuchs' Uveitis Syndrome: No Longer a Syndrome?Elke Olivia Kreps, Thierry Derveaux, Filip De Keyser, et al.
Best Practice & Research. Clinical Rheumatology|October 31, 2002
Ankylosing spondylitis and bowel diseaseDominique Baeten, Filip De Keyser, Herman Mielants, et al.
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Current Rheumatology Reviews|November 15, 2011
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection PerspectiveFilip De Keyser
Arthritis Research & Therapy|June 24, 2010
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritisIsabelle Delabaye, Filip De Keyser,
Current Molecular Medicine|March 12, 2004
The histopathology of spondyloarthropathyDominique Baeten, Filip De Keyser
Plos One|September 5, 2014
Assessment of activity limitations with the health assessment questionnaire predicts the need for support measures in patients with rheumatoid arthritis: a multicenter observational studyXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Clinical and Experimental Rheumatology|August 1, 2013
Construction and psychometric properties of the Belgian Rheumatoid Arthritis Disability Assessment (BRADA) questionnaire: a new tool for the evaluation of activity limitations in patients with rheumatoid arthritisXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Plos One|January 23, 2016
Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid ArthritisXavier Janssens, Saskia Decuman, Filip De Keyser, et al.
Cytokine|March 7, 2006
Anti-TNF-alpha therapy in ankylosing spondylitisFilip De Keyser, Filip Van den Bosch, Herman Mielants
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Ocular Immunology and Inflammation|July 30, 2015
Fuchs' Uveitis Syndrome: No Longer a Syndrome?Elke Olivia Kreps, Thierry Derveaux, Filip De Keyser, et al.
Best Practice & Research. Clinical Rheumatology|October 31, 2002
Ankylosing spondylitis and bowel diseaseDominique Baeten, Filip De Keyser, Herman Mielants, et al.
Pageof 11